• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Venus Concept Inc.

    5/30/25 7:00:18 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    SD 1 ef20049958_sd.htm SD
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    FORM SD

    Specialized Disclosure Report



    Venus Concept Inc.
    (Exact name of Registrant as specified in its charter)



    Delaware
    001-38238
    06-1681204
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    235 Yorkland Blvd, Suite 900
    Toronto, Ontario
    M2J 4Y8
    (Address of principal executive offices)
    (Zip Code)

    Michael Mandarello
    Chief Legal Officer and Head of Strategy & Operations
    (877) 848-8430
    (Name and telephone number, including area code, of the
    person to contact in connection with this report.)



    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ☒
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.



    Section 1
    Conflict Minerals Disclosure.

    Item 1.01
    Conflict Minerals Disclosure and Report.

    Conflict Minerals Disclosure

    This conflict minerals disclosure included in this specialized disclosure report for the year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Securities and Exchange Commission (“SEC”) adopted the Rule to implement reporting and disclosure requirements related to “Conflict Minerals” as directed by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”). The Dodd-Frank Act defines “Conflict Minerals” as columbite-tantalite (coltan), cassiterite, gold, wolframite and the derivatives tantalum, tin and tungsten, without regard to the location of origin of the minerals or derivative metals. The covered countries for the purposes of the Rule are the Democratic Republic of the Congo, the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia and Angola (“Covered Countries”). The Rule imposes certain reporting requirements on SEC registrants who manufacture or contract to manufacture products that include Conflict Minerals, if such Conflict Minerals are necessary to the functionality or production of the products.

    If a registrant has reason to believe that any Conflict Minerals necessary to the functionality or production of their products may have originated in the Covered Countries, or if they are unable to determine the country of origin of those minerals, then the registrant must exercise due diligence on the minerals’ source and chain of custody and submit a Conflict Minerals Report to the SEC that includes a description of those due diligence measures. Consistent with the provisions of the Rule, neither this specialized disclosure report, nor our reasonable country of origin inquiry (“RCOI”) has been audited by a third party.

    Venus Concept Inc. (“Venus,” “the Company,” “we,” “us,” or “our”) evaluated its product line and determined that within certain components and sub-components of these products, certain Conflict Minerals were necessary to the functionality or production of our products. Based on this assessment, we performed a RCOI in good faith, which we believe was appropriately designed to determine whether Conflict Minerals originated in the Covered Countries or are from recycled or scrap sources.

    Our products contain hundreds of components that are sourced by our product manufacturers and/or suppliers. Venus does not directly source Conflict Minerals, and is many levels removed from mines, smelters or refiners that produce the metals used in Venus’ products. While conducting our RCOI, we identified approximately 11 manufacturers or suppliers of our devices, components or sub-components which were identified as containing a Conflict Mineral. Venus utilized the reporting template created by the Responsible Minerals Initiative, which provides a common means for the collection of sourcing information on Conflict Minerals. We used the reporting templates and made inquiries of our manufacturers and suppliers of each device and component that contained a Conflict Mineral. The results of the data gathered were evaluated by a team comprised of operations and legal personnel.

    Based on the RCOI processes undertaken as described, for 2024, the Company has no reason to believe that Conflict Minerals necessary to the functionality or production of the Company’s products either (i) originated in the Covered Countries or (ii) were not from scrap or recycled materials.

    The above information and a copy of this Form SD may be found publicly on our website at https://ir.venusconcept.com/.

    Item 1.02
    Exhibit.

    Not required

    Section 2
    Exhibits.

    Item 2.01
    Exhibits.

    None


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    VENUS CONCEPT INC.
       
    Date: May 30, 2025
    /s/ Michael Mandarello
     
    Michael Mandarello
     
    Chief Legal Officer and Head of Strategy & Operations



    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces First Quarter 2025 Financial Results

      TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting continued difficult market conditions. First quarter operating expenses declined 6% year-over-yearFirst quarter GAAP net loss of $12.4 million, compared to $9.8 million last yearFirst quarter Adjusted EBITDA loss of $8.3 million, compared to $5.1 million last year On April 1, 2025, the Company exchanged $11.0 million of its sub

      5/15/25 7:00:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/6/25 5:07:51 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/2/25 4:28:55 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Venus Concept Inc.

      SD - Venus Concept Inc. (0001409269) (Filer)

      5/30/25 7:00:18 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care